Suppr超能文献

在癌症治疗中,利用天然来源的倍半萜内酯靶向程序性细胞死亡(RCD)。

Targeting regulated cell death (RCD) with naturally derived sesquiterpene lactones in cancer therapy.

作者信息

Xu Cong, Wen Shaodi, Du Xiaoyue, Zou Xinhua, Leung Elaine Lai-Han, Zhou Guoren, Wu Qibiao, Shen Bo

机构信息

Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210000, China; State Key Laboratory of Quality Research in Chinese Medicines and Faculty of Chinese Medicine, Macau University of Science and Technology, 999078, Macao.

Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210000, China.

出版信息

Pharmacol Res. 2025 Jan;211:107553. doi: 10.1016/j.phrs.2024.107553. Epub 2024 Dec 18.

Abstract

Regulated cell death (RCD) is a type of cell death modulated by specific signal transduction pathways. Currently, known RCD types include apoptosis, autophagy, ferroptosis, necroptosis, cuproptosis, pyroptosis, and NETosis. Mutations in cancer cells may prevent the RCD pathway; therefore, targeting RCD in tumors has become a promising therapeutic approach. Sesquiterpene lactones represent a diverse and extensive class of plant-derived phytochemicals that serve as potential sources for developing various drugs. Recent studies have shown that sesquiterpene lactones have promising potential in cancer treatment. This review systematically summarizes recent progress in the study of sesquiterpene lactones as antitumor agents, highlighting their role in targeting various RCD pathways, including those involved in apoptosis, autophagy, ferroptosis, necroptosis, and cuproptosis. The primary purpose of the present review is to provide a clear picture of the regulation of RCD by sesquiterpene lactones against different targets in various cancers, which will facilitate the development of new strategies for cancer therapy.

摘要

程序性细胞死亡(RCD)是一种由特定信号转导通路调节的细胞死亡类型。目前,已知的RCD类型包括细胞凋亡、自噬、铁死亡、坏死性凋亡、铜死亡、焦亡和中性粒细胞胞外陷阱形成。癌细胞中的突变可能会阻断RCD通路;因此,针对肿瘤中的RCD进行靶向治疗已成为一种有前景的治疗方法。倍半萜内酯是一类多样且广泛的植物源植物化学物质,是开发各种药物的潜在来源。最近的研究表明,倍半萜内酯在癌症治疗方面具有广阔的潜力。本综述系统地总结了倍半萜内酯作为抗肿瘤药物的研究进展,重点介绍了它们在靶向各种RCD通路中的作用,包括那些参与细胞凋亡、自噬、铁死亡、坏死性凋亡和铜死亡的通路。本综述的主要目的是清晰地呈现倍半萜内酯针对各种癌症中不同靶点对RCD的调节作用,这将有助于开发新的癌症治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验